JP7132630B2 - 同位体修飾成分及びその治療上の使用 - Google Patents

同位体修飾成分及びその治療上の使用 Download PDF

Info

Publication number
JP7132630B2
JP7132630B2 JP2019526314A JP2019526314A JP7132630B2 JP 7132630 B2 JP7132630 B2 JP 7132630B2 JP 2019526314 A JP2019526314 A JP 2019526314A JP 2019526314 A JP2019526314 A JP 2019526314A JP 7132630 B2 JP7132630 B2 JP 7132630B2
Authority
JP
Japan
Prior art keywords
fatty acid
pufa
polyunsaturated fatty
subject
aldh2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019526314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500193A5 (enExample
JP2020500193A (ja
Inventor
シチェピノフ、ミハイル、セルゲーエヴィチ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Retrotope Inc
Original Assignee
Retrotope Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Retrotope Inc filed Critical Retrotope Inc
Publication of JP2020500193A publication Critical patent/JP2020500193A/ja
Publication of JP2020500193A5 publication Critical patent/JP2020500193A5/ja
Priority to JP2022130995A priority Critical patent/JP7464661B2/ja
Application granted granted Critical
Publication of JP7132630B2 publication Critical patent/JP7132630B2/ja
Priority to JP2024052901A priority patent/JP2024081733A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90203—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
JP2019526314A 2016-11-17 2017-11-16 同位体修飾成分及びその治療上の使用 Active JP7132630B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022130995A JP7464661B2 (ja) 2016-11-17 2022-08-19 同位体修飾成分及びその治療上の使用
JP2024052901A JP2024081733A (ja) 2016-11-17 2024-03-28 同位体修飾成分及びその治療上の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423699P 2016-11-17 2016-11-17
US62/423,699 2016-11-17
PCT/US2017/062107 WO2018094116A1 (en) 2016-11-17 2017-11-16 Isotopically modified components and therapeutic uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022130995A Division JP7464661B2 (ja) 2016-11-17 2022-08-19 同位体修飾成分及びその治療上の使用

Publications (3)

Publication Number Publication Date
JP2020500193A JP2020500193A (ja) 2020-01-09
JP2020500193A5 JP2020500193A5 (enExample) 2020-12-17
JP7132630B2 true JP7132630B2 (ja) 2022-09-07

Family

ID=62145748

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019526314A Active JP7132630B2 (ja) 2016-11-17 2017-11-16 同位体修飾成分及びその治療上の使用
JP2022130995A Active JP7464661B2 (ja) 2016-11-17 2022-08-19 同位体修飾成分及びその治療上の使用
JP2024052901A Pending JP2024081733A (ja) 2016-11-17 2024-03-28 同位体修飾成分及びその治療上の使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022130995A Active JP7464661B2 (ja) 2016-11-17 2022-08-19 同位体修飾成分及びその治療上の使用
JP2024052901A Pending JP2024081733A (ja) 2016-11-17 2024-03-28 同位体修飾成分及びその治療上の使用

Country Status (6)

Country Link
US (2) US11166930B2 (enExample)
JP (3) JP7132630B2 (enExample)
KR (1) KR102580606B1 (enExample)
CN (1) CN110167546A (enExample)
AU (2) AU2017363147B2 (enExample)
WO (1) WO2018094116A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3536317A1 (en) * 2009-10-30 2019-09-11 Retrotope, Inc. Alleviating oxidative stress disorders with pufa derivatives
KR102580606B1 (ko) 2016-11-17 2023-09-19 레트로토프 인코포레이티드 동위원소로 변형된 성분 및 이의 치료학적 용도
US20210252173A1 (en) * 2018-04-20 2021-08-19 Retrotope, Inc. Stabilized polyunsaturated compounds and uses thereof
CN109601803A (zh) * 2018-11-07 2019-04-12 江西颐迪科技有限公司 一种能消除老年人体味并有助健康的饮料及其制作方法
US20220009950A1 (en) * 2018-11-15 2022-01-13 Retrotope, Inc. Deuterated compounds, compositions, and methods of use
EP3947683A1 (en) * 2019-04-04 2022-02-09 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression in the central nervous system
EP4103145A4 (en) * 2020-02-12 2024-07-03 Retrotope, Inc. DEUTERATED POLYUNSATURATED FATTY ACIDS OR THEIR ESTERS FOR COSMETIC APPLICATIONS
IL295512A (en) * 2020-02-14 2022-10-01 Retrotope Inc Methods for treating tauopathy
US11510889B2 (en) 2021-02-05 2022-11-29 Retrotope, Inc. Methods for inhibiting the progression of neurodegenerative diseases
US11351143B1 (en) * 2021-02-05 2022-06-07 Retrotope, Inc. Methods of treating amyotrophic lateral sclerosis
US11491130B2 (en) 2021-02-05 2022-11-08 Retrotope, Inc. Methods of treating amyotrophic lateral sclerosis
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
WO2022170134A2 (en) * 2021-02-05 2022-08-11 Retrotope, Inc. Dosing protocols for administering deuterated arachidonic acid or a prodrug thereof
US20230301956A1 (en) * 2021-12-21 2023-09-28 Biojiva Llc Methods and compositions for treatment of inflammatory disease
WO2023158641A1 (en) * 2022-02-15 2023-08-24 Retrotope, Inc. Synergistic combination therapy for treating als
JP2025540042A (ja) * 2022-12-01 2025-12-11 ピコエンテック シーオー．，エルティーディー． 内因性アルデヒドを解毒するための食品組成物および医薬組成物
KR20250110548A (ko) 2024-01-12 2025-07-21 현대모비스 주식회사 전기자동차용 배터리팩 케이스

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013189437A (ja) 2005-07-29 2013-09-26 Tima Foundation アルコール代謝を和らげる、およびアルコール誘発性疾患のリスクを減少させるための組成物
JP2014502974A (ja) 2011-01-24 2014-02-06 インセプタム リサーチ アンド セラピューティクス，インク． 精神神経性の疾病を処置するためのプロスタグランジンを含む組成物
JP2016138138A (ja) 2009-10-30 2016-08-04 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． Ｐｕｆａ誘導体による酸化ストレス障害の緩和

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069208A1 (en) 1997-11-25 2003-04-10 University Of Otago Mitochondrially targeted antioxidants
US6331532B1 (en) 1998-11-25 2001-12-18 University Of Otago Mitochondrially targeted antioxidants
AU750313B2 (en) 1998-07-27 2002-07-18 St. Jude Pharmaceuticals, Inc. Chemically induced intracellular hyperthermia
US20070270381A1 (en) 2000-05-25 2007-11-22 Antipodean Pharmaceuticals, Inc. Mitochondrially targeted antioxidants
US20080275005A1 (en) 1998-11-25 2008-11-06 Murphy Michael P Mitochondrially targeted antioxidants
US20060229278A1 (en) 1998-11-25 2006-10-12 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
US6544764B2 (en) 2000-11-14 2003-04-08 Applera Corporation Isolated human dehydrogenase proteins, nucleic acid molecules encoding these human dehydrogenase proteins, and uses thereof
US20030032078A1 (en) * 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
NZ513547A (en) 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)
IL173807A (en) 2003-08-22 2014-02-27 Antipodean Pharmaceuticals Inc Antioxidant amphiphilic compounds, histoquinone history and pharmaceutical preparations containing them
US7888334B2 (en) 2003-08-22 2011-02-15 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
WO2005032544A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Treatment of mitochondrial diseases
LT1933821T (lt) 2005-09-15 2020-11-10 Ptc Therapeutics, Inc. Šoninės grandinės variantai redoks aktyviųjų terapijos priemonių, skirtų mitochondrinių ligų ir kitokių būklių gydymui ir energijos biologinių žymenų moduliavimui
WO2009089224A1 (en) 2008-01-08 2009-07-16 Edison Pharmaceuticals, Inc. (HET) ARYL-p-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
CN102046178B (zh) 2008-04-01 2013-05-08 安蒂博汀医药公司 用于皮肤护理的组合物和方法
US8124389B2 (en) 2008-05-07 2012-02-28 The Board Of Trustees Of The Leland Stanford Junior University Crystal structure of aldehyde dehydrogenase and methods of use thereof
US20100029706A1 (en) 2008-07-30 2010-02-04 Edison Parmaceuticals, Inc. a Delaware Corporation HYDROGENATED PYRIDO[4,3-b]INDOLES FOR THE TREATMENT OF OXIDATIVE STRESS
US20120005765A1 (en) * 2010-07-01 2012-01-05 Saint Louis University Animal model for parkinson's disease
AU2012249921B2 (en) * 2011-04-26 2017-06-08 Biojiva Llc Oxidative retinal diseases
AU2012249920B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Disorders implicating PUFA oxidation
JP6106157B2 (ja) 2011-04-26 2017-03-29 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． 神経変性障害および筋疾患に関与するｐｕｆａ
KR102580606B1 (ko) 2016-11-17 2023-09-19 레트로토프 인코포레이티드 동위원소로 변형된 성분 및 이의 치료학적 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013189437A (ja) 2005-07-29 2013-09-26 Tima Foundation アルコール代謝を和らげる、およびアルコール誘発性疾患のリスクを減少させるための組成物
JP2016138138A (ja) 2009-10-30 2016-08-04 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． Ｐｕｆａ誘導体による酸化ストレス障害の緩和
JP2014502974A (ja) 2011-01-24 2014-02-06 インセプタム リサーチ アンド セラピューティクス，インク． 精神神経性の疾病を処置するためのプロスタグランジンを含む組成物

Also Published As

Publication number Publication date
US11166930B2 (en) 2021-11-09
US20220133668A1 (en) 2022-05-05
AU2017363147A1 (en) 2019-05-23
US20190282529A1 (en) 2019-09-19
AU2017363147B2 (en) 2023-09-14
JP2020500193A (ja) 2020-01-09
JP2022166245A (ja) 2022-11-01
KR102580606B1 (ko) 2023-09-19
JP7464661B2 (ja) 2024-04-09
CN110167546A (zh) 2019-08-23
WO2018094116A1 (en) 2018-05-24
JP2024081733A (ja) 2024-06-18
AU2023282263A1 (en) 2024-01-18
KR20190085973A (ko) 2019-07-19

Similar Documents

Publication Publication Date Title
JP7464661B2 (ja) 同位体修飾成分及びその治療上の使用
US20250325512A1 (en) Neurodegenerative Disorders And Muscle Diseases Implicating Pufas
US20220304968A1 (en) Oxidative retinal diseases
AU2019204443B2 (en) Optic neuropathy treatment and reduction of steroid-induced oxidative stress with stabilized polyunsaturated substances
HK40011999A (en) Isotopically modified components and therapeutic uses thereof
HK1233443B (en) Optic neuropathy treatment and reduction of steroid-induced oxidative stress with stabilized polyunsaturated substances
HK1195011B (en) Neurodegenerative disorders and muscle diseases implicating pufas
HK1195011A (en) Neurodegenerative disorders and muscle diseases implicating pufas
HK1195018A (en) Oxidative retinal diseases
HK1195018B (en) Oxidative retinal diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211026

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220420

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220720

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220819

R150 Certificate of patent or registration of utility model

Ref document number: 7132630

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250